Compare Abbott India with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs STRIDES PHARMA SCIENCE - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA STRIDES PHARMA SCIENCE ABBOTT INDIA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 49.0 47.9 102.2% View Chart
P/BV x 15.8 2.2 707.2% View Chart
Dividend Yield % 0.4 0.2 200.1%  

Financials

 ABBOTT INDIA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
ABBOTT INDIA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8,8341,147 770.2%   
Low Rs5,458642 850.1%   
Sales per share (Unadj.) Rs1,731.1317.2 545.7%  
Earnings per share (Unadj.) Rs211.97.8 2,701.4%  
Cash flow per share (Unadj.) Rs219.925.1 877.6%  
Dividends per share (Unadj.) Rs65.002.00 3,250.0%  
Dividend yield (eoy) %0.90.2 406.8%  
Book value per share (Unadj.) Rs945.2274.3 344.7%  
Shares outstanding (eoy) m21.2589.50 23.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.8 146.4%   
Avg P/E ratio x33.7114.0 29.6%  
P/CF ratio (eoy) x32.535.7 91.0%  
Price / Book Value ratio x7.63.3 231.8%  
Dividend payout %30.725.5 120.3%   
Avg Mkt Cap Rs m151,84880,058 189.7%   
No. of employees `0003.52.5 139.0%   
Total wages/salary Rs m4,3564,341 100.4%   
Avg. sales/employee Rs Th10,555.511,325.8 93.2%   
Avg. wages/employee Rs Th1,249.91,731.4 72.2%   
Avg. net profit/employee Rs Th1,292.2280.1 461.4%   
INCOME DATA
Net Sales Rs m36,78628,394 129.6%  
Other income Rs m1,133941 120.4%   
Total revenues Rs m37,91929,334 129.3%   
Gross profit Rs m6,0473,965 152.5%  
Depreciation Rs m1691,540 11.0%   
Interest Rs m231,962 1.1%   
Profit before tax Rs m6,9891,403 498.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m2,48597 2,554.2%   
Profit after tax Rs m4,503702 641.4%  
Gross profit margin %16.414.0 117.7%  
Effective tax rate %35.66.9 512.8%   
Net profit margin %12.22.5 495.1%  
BALANCE SHEET DATA
Current assets Rs m27,61024,836 111.2%   
Current liabilities Rs m8,56918,993 45.1%   
Net working cap to sales %51.820.6 251.5%  
Current ratio x3.21.3 246.4%  
Inventory Days Days6071 84.8%  
Debtors Days Days27113 24.2%  
Net fixed assets Rs m1,05734,289 3.1%   
Share capital Rs m213895 23.7%   
"Free" reserves Rs m19,87323,651 84.0%   
Net worth Rs m20,08624,546 81.8%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m29,40965,437 44.9%  
Interest coverage x311.61.7 18,168.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.4 288.3%   
Return on assets %15.44.1 377.9%  
Return on equity %22.42.9 783.8%  
Return on capital %34.96.9 506.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36915,697 2.4%   
Fx outflow Rs m4,918735 668.8%   
Net fx Rs m-4,54914,962 -30.4%   
CASH FLOW
From Operations Rs m4,9911,871 266.8%  
From Investments Rs m-2,5705,826 -44.1%  
From Financial Activity Rs m-1,428-10,157 14.1%  
Net Cashflow Rs m993-2,615 -38.0%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 37.8 20.9%  
FIIs % 0.1 8.6 1.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 25.9 66.0%  
Shareholders   18,270 56,241 32.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Apr 16, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS